Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Perspective Therapeutics (CATX) Equity Average (2016 - 2026)

Perspective Therapeutics' Equity Average history spans 15 years, with the latest figure at $277.2 million for Q1 2026.

  • On a quarterly basis, Equity Average fell 3.62% to $277.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $277.2 million, a 3.62% decrease, with the full-year FY2025 number at $248.8 million, up 36.04% from a year prior.
  • Equity Average hit $277.2 million in Q1 2026 for Perspective Therapeutics, up from $224.6 million in the prior quarter.
  • Over the last five years, Equity Average for CATX hit a ceiling of $334.7 million in Q3 2024 and a floor of $56.2 million in Q4 2022.
  • Historically, Equity Average has averaged $178.4 million across 5 years, with a median of $152.5 million in 2024.
  • Biggest five-year swings in Equity Average: surged 255.93% in 2024 and later decreased 27.44% in 2025.
  • Tracing CATX's Equity Average over 5 years: stood at $56.2 million in 2022, then skyrocketed by 54.84% to $87.0 million in 2023, then surged by 255.93% to $309.6 million in 2024, then fell by 27.44% to $224.6 million in 2025, then rose by 23.42% to $277.2 million in 2026.
  • Business Quant data shows Equity Average for CATX at $277.2 million in Q1 2026, $224.6 million in Q4 2025, and $254.0 million in Q3 2025.